ObsEva Randomizes First Patient in Phase 2b EDELWEISS Study of OBE2109 for the Treatment of Endometriosis
October 12, 2016
Clinical trial to assess safety and efficacy of novel GnRH antagonist in patients with pelvic pain associated with endometriosis
GENEVA, SWITZERLAND, 12 October, 2016
ObsEva SA, a Swiss biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced randomization of the first patient in its Phase 2b clinical study (EDELWEISS) of OBE2109 for the treatment of endometriosis. OBE2109 is a novel, orally administered, gonadotropin-releasing hormone (GnRH) antagonist that has been tested in more than 150 Japanese patients with endometriosis. In those Phase 2a studies, conducted by Kissei Pharmaceutical Co., Ltd. (Kissei), a dose-dependent suppression of estradiol was observed with treatment with OBE2109. In addition, patients reported significant reductions of endometriosis-associated pelvic pain, analgesic use and bleeding days.
Read the full news release.